JP2024517345A - Ｃｏｖｉｄ－１９ワクチンのための新規のタンパク質および核酸配列 - Google Patents

Ｃｏｖｉｄ－１９ワクチンのための新規のタンパク質および核酸配列 Download PDF

Info

Publication number
JP2024517345A
JP2024517345A JP2023570240A JP2023570240A JP2024517345A JP 2024517345 A JP2024517345 A JP 2024517345A JP 2023570240 A JP2023570240 A JP 2023570240A JP 2023570240 A JP2023570240 A JP 2023570240A JP 2024517345 A JP2024517345 A JP 2024517345A
Authority
JP
Japan
Prior art keywords
seq
amino acid
cov
sars
protein
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2023570240A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024517345A5 (enExample
Inventor
アレグレッティ，マルチェッロ
チミニ，アンナマリア
ベッカーリ，アンドレア・ロザリオ
タラリコ，カルミネ
マウリ，エリザベッタ・マリア・エステル
カッターニ，フランカ
Original Assignee
ドムペ・ファルマチェウティチ・ソチエタ・ペル・アツィオーニ
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ドムペ・ファルマチェウティチ・ソチエタ・ペル・アツィオーニ filed Critical ドムペ・ファルマチェウティチ・ソチエタ・ペル・アツィオーニ
Publication of JP2024517345A publication Critical patent/JP2024517345A/ja
Publication of JP2024517345A5 publication Critical patent/JP2024517345A5/ja
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/215—Coronaviridae, e.g. avian infectious bronchitis virus
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/20011—Coronaviridae
    • C12N2770/20022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/20011—Coronaviridae
    • C12N2770/20034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Communicable Diseases (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Pulmonology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2023570240A 2021-05-14 2022-05-16 Ｃｏｖｉｄ－１９ワクチンのための新規のタンパク質および核酸配列 Pending JP2024517345A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP21173941.2A EP4088738A1 (en) 2021-05-14 2021-05-14 Novel protein and nucleic acid sequences for covid-19 vaccines
EP21173941.2 2021-05-14
PCT/EP2022/063214 WO2022238585A1 (en) 2021-05-14 2022-05-16 Novel protein and nucleic acid sequences for covid-19 vaccines

Publications (2)

Publication Number Publication Date
JP2024517345A true JP2024517345A (ja) 2024-04-19
JP2024517345A5 JP2024517345A5 (enExample) 2025-04-21

Family

ID=75936784

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023570240A Pending JP2024517345A (ja) 2021-05-14 2022-05-16 Ｃｏｖｉｄ－１９ワクチンのための新規のタンパク質および核酸配列

Country Status (10)

Country Link
US (1) US20250282831A1 (enExample)
EP (2) EP4088738A1 (enExample)
JP (1) JP2024517345A (enExample)
CN (1) CN117915945A (enExample)
AU (1) AU2022272659A1 (enExample)
BR (1) BR112023023794A2 (enExample)
CA (1) CA3219586A1 (enExample)
IL (1) IL308407A (enExample)
WO (1) WO2022238585A1 (enExample)
ZA (1) ZA202311432B (enExample)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2024245344A1 (zh) * 2023-05-30 2024-12-05 石药集团巨石生物制药有限公司 预防新型冠状病毒奥密克戎突变株的mRNA疫苗

Non-Patent Citations (6)

* Cited by examiner, † Cited by third party
Title
AMANAT F. ET AL.: "Introduction of Two Prolines and Removal of the Polybasic Cleavage Site Lead to Highr Efficacy of a", MBIO, vol. vol.12:e02648-20, JPN6026010779, 2 March 2021 (2021-03-02), pages 1 - 10, ISSN: 0005819986 *
HONG S. ET AL.: "Raloxifene as a treatment option for viral infections", J MICROBIOL, vol. vol.59(2), JPN6026010774, 1 February 2021 (2021-02-01), pages 124 - 131, ISSN: 0005819981 *
HSIEH CL. ET AL.: "Structure-based design of prefusion-stabilized SARS-CoV-2 spikes", SCIENCE, vol. vol.369(6510), JPN6026010775, 18 September 2020 (2020-09-18), pages 1501 - 1505, ISSN: 0005819982 *
MOHAMED MS. ET AL.: "Sex differences in COVID-19: the role of androgens in disease severity and progression", ENDOCRINE, vol. vol.71(1), JPN6026010778, January 2021 (2021-01-01), pages 3 - 8, ISSN: 0005819985 *
SANDERS RW. ET AL.: "Virus vaccines: proteins prefer prolines", CELL HOST MICROBE, vol. vol.29(3), JPN6026010777, 10 March 2021 (2021-03-10), pages 327 - 333, ISSN: 0005819984 *
XIA X.: "Domains and Functions of Spike Protein in Sars-Cov-2 in the Context of Vaccine Design", VIRUSES, vol. vol.13(1):109, JPN6026010776, 14 January 2021 (2021-01-14), pages 1 - 16, ISSN: 0005819983 *

Also Published As

Publication number Publication date
EP4088738A1 (en) 2022-11-16
CN117915945A (zh) 2024-04-19
CA3219586A1 (en) 2022-11-17
AU2022272659A1 (en) 2023-11-23
WO2022238585A1 (en) 2022-11-17
AU2022272659A9 (en) 2023-11-30
ZA202311432B (en) 2025-04-30
US20250282831A1 (en) 2025-09-11
IL308407A (en) 2024-01-01
BR112023023794A2 (pt) 2024-03-12
EP4337250A1 (en) 2024-03-20

Similar Documents

Publication Publication Date Title
Liu et al. Protective T cell responses featured by concordant recognition of Middle East respiratory syndrome coronavirus–derived CD8+ T cell epitopes and host MHC
Goto et al. Contribution of the exosome-associated form of secreted endoplasmic reticulum aminopeptidase 1 to exosome-mediated macrophage activation
CN106573960A (zh) 用于针对乙型肝炎病毒感染的治疗性接种的合成长肽(slp)
Dalvie et al. Molecular engineering improves antigen quality and enables integrated manufacturing of a trivalent subunit vaccine candidate for rotavirus
US9624272B2 (en) Polypeptides for treating and/or limiting influenza infection
KR20240163165A (ko) 에피토프의 조합과 그의 용도, 백신 구조물, 면역 반응의 유도 방법 에피토프의 식별 방법
JP2009525725A (ja) 血小板抗原特異抗体の結合を中和するペプチドアプタマー並びにそれを含む診断及び治療への応用
US20240180889A1 (en) Combination therapy for covid-19 vaccination
US20250282831A1 (en) Novel protein and nucleic acid sequences for covid-19 vaccines
KR20070056107A (ko) Ｂ형 간염 바이러스 ｓ 항원의 검출법
AU2021268753A1 (en) Bioinformatics
Shah et al. Overexpression and characterization of the 100K protein of Fowl adenovirus-4 as an antiviral target
Ganguly et al. Enhanced prokaryotic expression of dengue virus envelope protein
US20220339279A1 (en) Recombinant proteins, compositions, vectors, kits, and methods for immunizing against, and testing for exposure to, severe acute respiratory syndrome coronavirus 2
CN113943349A (zh) 靶向识别抗新冠病毒中和抗体N-IgY-pAbs的核心氨基酸序列组及应用
Gui et al. Identification of a highly conserved and surface exposed B‐cell epitope on the nucleoprotein of influenza A virus
Saleh et al. Expression of HCV genotype-4 core antigen in prokaryotic E. coli system for diagnosis of HCV infection in Egypt
Chai et al. Preparation and identification of polyclonal antibody against human cytomegalovirus encoding protein UL23
CN116813767A (zh) 一种fgf21蛋白多克隆抗体制备方法
US20100152110A1 (en) Alternate reading frame polypeptides derived from hepatitis c and methods of their use
CN121494944B (zh) 一种马尔堡gp蛋白突变体、dna分子、重组载体及其应用
WO2010118404A2 (en) Methods for creating or identifying compounds that bind tumor necrosis factor alpha
US7198891B2 (en) Hepatitis C virus peptides and uses thereof
RU2856219C1 (ru) Рекомбинантная плазмидная ДНК pET-22b-sars"XBB.1.5", обеспечивающая получение рекомбинантного белка коронавируса S-SARS"XBB.1.5", обладающего способностью определять уровень вирус-специфических IgG к антигенному варианту вируса "кракен" - SARS"XBB.1.5"
CN119751703A (zh) 一种重组蛋白、核酸分子和重组噬菌体及其应用

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250411

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20250411

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20260318

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20260616